Highlight
This real-world, multicentre study demonstrates that initiation of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease is associated with a slower decline in estimated glomerular filtration rate (eGFR) and significant improvements in albuminuria compared with other glucose-lowering medications, including GLP-1 receptor agonists (GLP-1RA). These data reinforce SGLT2 inhibitors as a key therapeutic option to preserve kidney function and delay CKD progression in this high-risk population.
